Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | ERN1 | O75460 | 8/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1048291 | 0.93 | PRKDC (0.56) | PRKDCALDH1A1KDM4ETSHRTDP1 | |
| SCHEMBL566132 | 0.85 | PRKDC (0.72) | PRKDCALDH1A1KDM4ETSHRTDP1 | |
| SCHEMBL71268 | 0.84 | ALDH1A1 (0.65) | PRKDCALDH1A1KDM4ETSHRTDP1 | |
| SCHEMBL29636410 | 0.84 | ALDH1A1 (0.65) | PRKDCALDH1A1KDM4ETSHRTDP1 | |
| SCHEMBL1516891 | 0.84 | PRKDC (0.47) | PRKDCALDH1A1KDM4ETSHRTDP1 | |
| SCHEMBL698744 | 0.82 | PRKDC (0.81) | PRKDCALDH1A1KDM4ETSHRTDP1 | |
| SCHEMBL2915368 | 0.82 | ALDH1A1 (0.57) | PRKDCALDH1A1KDM4ETSHRTDP1 | |
| SCHEMBL2037836 | 0.82 | PRKDC (0.74) | PRKDCALDH1A1KDM4ETSHRTDP1 | |
| SCHEMBL3577518 | 0.82 | LMNA (0.45) | PRKDCALDH1A1KDM4ETSHRTDP1 | |
| SCHEMBL436131 | 0.80 | ALDH1A1 (0.54) | PRKDCALDH1A1KDM4ETSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250276966-A1 | Nitrogen-Linked Benzisoxazole Sulfonamide Derivatives | PFIZER (US) | 2025-09-04 | — | — | US | disclosed |
| CN-115427035-B | ENL/AF9 YEATS inhibitors | 洛克菲勒大学 | 2025-04-22 | — | — | CN | disclosed |
| US-20250122183-A1 | Nitrogen-Linked Benzisoxazole Sulfonamide Derivatives | PFIZER (US) | 2025-04-17 | — | — | US | disclosed |
| WO-2025074249-A1 | NITROGEN-LINKED BENZISOXAZOLE SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF CANCER | PFIZER INC. (US) | 2025-04-10 | — | — | WO | disclosed |
| US-11839613-B2 | Pyrimidine derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-12-12 | — | — | US | disclosed |
| EP-3911413-B1 | SUBSTITUTED CHROMEN-4-ONE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2023-12-06 | — | — | EP | disclosed |
| CN-117088884-A | Imidazopyridazine derivatives as GABAA receptor modulators, pharmaceutical compositions and uses | 上海赛默罗德生物科技有限公司 | 2023-11-21 | — | — | CN | disclosed |
| EP-4257588-A1 | SMALL MOLECULE INHIBITOR OF CATHEPSIN C AND MEDICINAL USE THEREOF | Reistone Biopharma Company Limited (CN) | 2023-10-11 | — | — | EP | disclosed |
| US-11712438-B2 | Phenyl derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-08-01 | — | — | US | disclosed |
| CN-111971277-B | Benzothiophenes and related compounds as STING agonists | 默沙东有限责任公司 | 2023-06-06 | — | — | CN | disclosed |
| US-20070015764-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | AGOURON PHARMACEUTICALS, INC. | 2007-01-18 | — | — | US | disclosed |
| US-7151105-B2 | Inhibitors of Hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. (US) | 2006-12-19 | — | — | US | disclosed |
| US-7148226-B2 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. (US) | 2006-12-12 | — | — | US | disclosed |
| US-20060189681-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | AGOURON PHARMACEUTICALS, INC. | 2006-08-24 | — | — | US | disclosed |
| US-20060122399-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. | 2006-06-08 | — | — | US | disclosed |
| WO-2006018725-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| EP-1597246-A2 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2005-11-23 | — | — | EP | disclosed |
| US-20050176701-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. | 2005-08-11 | — | — | US | disclosed |
| US-20040224960-A1 | Pharmaceutical compositions and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2004-11-11 | — | — | US | disclosed |
| WO-2004074270-A2 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11712438-B2 | Phenyl derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | PRKDC 4874/4885ALDH1A1 575/4885KDM4E 842/4885 |
| US-20060122399-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | RNASE1, GTF3C4, POLRMT | PRKDC 2480/4885ALDH1A1 792/4885KDM4E 858/4885 |
| US-20070015764-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | RNASE1, GTF3C4, POLRMT | PRKDC 2480/4885ALDH1A1 792/4885KDM4E 858/4885 |
| US-11839613-B2 | Pyrimidine derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | PRKDC 4809/4885ALDH1A1 468/4885KDM4E 1571/4885 |
| US-20040224960-A1 | Pharmaceutical compositions and methods for their use | CYP3A5, CYP3A7, CYP3A43 | PRKDC 3409/4885ALDH1A1 154/4885KDM4E 1817/4885 |
| US-20250122183-A1 | Nitrogen-Linked Benzisoxazole Sulfonamide Derivatives | CCNI, MKI67, CCNA1 | PRKDC 3921/4885ALDH1A1 761/4885KDM4E 1058/4885 |
| US-20250276966-A1 | Nitrogen-Linked Benzisoxazole Sulfonamide Derivatives | CCNI, MKI67, CCNA1 | PRKDC 3976/4885ALDH1A1 792/4885KDM4E 1083/4885 |
| US-20060189681-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | RNASE1, RNASEH1, NSUN3 | PRKDC 3088/4885ALDH1A1 322/4885KDM4E 1534/4885 |
| US-20050176701-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | RNASE1, RNASEH1, NSUN3 | PRKDC 3088/4885ALDH1A1 322/4885KDM4E 1534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.